Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antiparasitic Drugs Market

Antiparasitic Drugs Market Share

Report ID: GMI8043
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Antiparasitic Drugs Market Share

The antiparasitic drugs industry is characterized by diverse players competing in the industry. Novartis AG, GlaxoSmithKline plc, Merck KGaA, and Zydus Group account for significant market share. These prominent players adopt a combination of strategic initiatives such as collaboration & partnership, global expansion, research and development, product diversification, and regulatory compliance to maintain a competitive edge in the market.

Antiparasitic Drugs Market Companies

Foremost players operating in the antiparasitic drugs industry are as mentioned below:

Bayer AG
Cipla Inc.
Dr. Reddy’s Laboratories Ltd
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd
Ipca Laboratories Ltd.
Mankind Pharma
Merck KGaA
Novartis AG
Sanofi
Zydus Group

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for antiparasitic drugs was valued at USD 22.7 billion in 2023 and is estimated to grow at a CAGR of 5.7% between 2024 and 2032, attributed to the rising prevalence of parasitic infections, and increasing public awareness campaigns and educational programs.

The anthelminthics segment held the largest market share of 50.2% in 2023 and will record strong growth through 2032 as helminthic infections, caused by parasitic worms, are widespread in many parts of the world, especially in tropical and subtropical regions.

In 2023, North America held a significant share of 36.8% in the global antiparasitic drugs industry and will grow significantly through 2032 attributed to increasing cases of parasitic infections in the region.

Bayer AG, Cipla Inc., Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd, Ipca Laboratories Ltd., Mankind Pharma, Merck KGaA, Novartis AG, Sanofi, and Zydus Group.